MSLN and melanoma: Initial cancer vaccines predominantly targeted proteins expressed at higher levels in tumors compared with normal tissue, so-called tumor-associated antigens (TAA), such as gp100 in melanoma or mesothelin in pancreatic cancer (2, 3).